Direct and Indirect Pathogenicity of ??-Lactamase-Producing Bacteria in Respiratory Tract Infection in Children

Stefani, Stefania; Pellegrino, M. B.; Russo, Giovanni; Nicoletti, Giuseppe

doi:10.2165/00003495-199100424-00006

Cited by 10 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30,31,52,53 For example, Mcat confers b-lactam resistance to other otopathogens, which may be a contributing factor in treatment failures of OM. 30,31,[64][65][66][67] Therefore, vaccination against Mcat may enhance the success rate of antimicrobial treatment in OM by eliminating or reducing the presence of an organism capable of conferring passive resistance to otherwise susceptible pathogens during coinfection.…”

Section: Clinical Manifestations Of Mcat Infectionmentioning

confidence: 99%

A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges

Perez

Murphy

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Moraxella catarrhalis is a major cause of morbidity and mortality worldwide, especially causing otitis media in young children and exacerbations of chronic obstructive pulmonary disease in adults. This pathogen uses several virulence mechanisms to colonize and survive in its host, including adherence and invasion of host cells, formation of polymicrobial biofilms with other bacterial pathogens, and production of β-lactamase. Given the global impact of otitis media and COPD, an effective vaccine to prevent M. catarrhalis infection would have a huge impact on the quality of life in both patient populations by preventing disease, thus reducing morbidity and health care costs. A number of promising vaccine antigens have been identified for M. catarrhalis. The development of improved animal models of M. catarrhalis disease and identification of a correlate of protection are needed to accelerate vaccine development. This review will discuss the current state of M. catarrhalis vaccine development, and the challenges that must be addressed to succeed.

show abstract

Section: Clinical Manifestations Of Mcat Infectionmentioning

confidence: 99%

A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges

Perez

Murphy

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Diuretic Treatment for the Sodium Retention of Congestive Heart Failure

Cody

Kubo²,

Pickworth³

1994

Arch Intern Med

View full text Add to dashboard Cite

The use of diuretics for the treatment of sodium retention in congestive heart failure was evaluated. Particular focus was given to the altered renal response to diuretics in patients with heart failure and adverse responses to diuretic therapy. Highlighted information included historical aspects of the development of diuretics, mechanisms of sodium retention, the physiologic and clinical response to diuretics, and the altered pharmacokinetics and pharmacodynamics of diuretics in congestive heart failure. Despite more than 60 years of empiric diuretic use in heart failure, the actual database regarding the long-term efficacy, adverse effects, and altered mortality outcome in heart failure is relatively small. Existent pharmacokinetic and pharmacodynamic data are typically not collected within the context of heart failure efficacy trials. In addition to altered electrolyte transport and total-body electrolyte depletion, diuretics may be associated with adverse neurohormonal activation. Thus, guidelines for acute and long-term therapy with diuretics in heart failure remain somewhat empiric. Diuretics will remain a mainstay for the treatment of edema in congestive heart failure but must be accompanied by moderate sodium restriction. However, large clinical trials of diuretics would be necessary to demonstrate that improved clinical efficacy with edema reduction is not offset by adverse effects, which include electrolyte depletion, ventricular arrhythmias, and subsequent increased mortality.

show abstract

Moraxella (Branhamella) catarrhalis

Zoutman

Community-Acquired Pneumonia

View full text Add to dashboard Cite

Direct and Indirect Pathogenicity of ??-Lactamase-Producing Bacteria in Respiratory Tract Infection in Children

Cited by 10 publications

References 13 publications

A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges

A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges

Diuretic Treatment for the Sodium Retention of Congestive Heart Failure

Moraxella (Branhamella) catarrhalis

Contact Info

Product

Resources

About